Skip to content

Study · Not a test of the peptide alone · 1975

6 results

Diagnostic value of intravenous glucagon test in insulinoma.

Oneda A, Maruhama Y, Itabashi H, Horigome K, Yanbe A

The Tohoku journal of experimental medicine1 Jul 1975Cited by 4 (Europe PMC)

PMID170711 (opens in a new tab)DOI10.1620/tjem.116.205 (opens in a new tab)PepBankPUB-00170711
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone6

In this study, Glucagon was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Glucagon.

  1. 01HumanNot a test of Glucagon aloneNon-randomized trialActivity measurement

    After glucagon, maximal plasma insulin ranged from 85 to 400 muU/ml in patients with insulinoma.

    In plain wordsAfter glucagon, maximum insulin ranged from 85 to 400 muU/ml in patients with insulinoma.

    Peptide
    Glucagon
    Outcome
    Not applicableMaximum plasma insulin
    Study

    n = 11

    Outcome group
    Glycemic control · Endocrine and hormones

    Measurements

    Maximum plasma insulin
    85 to 400 muU/ml
    insulinoma

    Source sentences

    Summary
    The maximal levels of plasma insulin ranged from 85 to 400 muU/ml, exceeding the normal range in 10 out of 11 patients, or 91%.
    1 context sentence
    Summary · context
    The intravenous glucagon test was performed in 11 patients with insulinoma and the diagnostic significance of the test was studied in comparison with the glucose test, the tolbutamide test and the arginine test.

    In this study, Glucagon was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Glucagon.

  2. 02HumanNot a test of Glucagon aloneNon-randomized trialActivity measurement

    After glucagon, maximal plasma insulin exceeded the normal range in 10 of 11 insulinoma patients, or 91%.

    In plain wordsAfter glucagon, maximum insulin exceeded the normal range in 10 of 11 patients with insulinoma.

    Peptide
    Glucagon
    Outcome
    Not applicableAbnormally high maximum insulin response proportion
    Study

    n = 11

    Comparator
    Normal range
    Outcome group
    Glycemic control · Endocrine and hormones

    Measurements

    Patients exceeding normal range
    10 patients
    11 patients
    Abnormal response proportion
    91%
    insulinoma

    Source sentences

    Summary
    The maximal levels of plasma insulin ranged from 85 to 400 muU/ml, exceeding the normal range in 10 out of 11 patients, or 91%.
    1 context sentence
    Summary · context
    The intravenous glucagon test was performed in 11 patients with insulinoma and the diagnostic significance of the test was studied in comparison with the glucose test, the tolbutamide test and the arginine test.

    In this study, Glucagon was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Glucagon.

  3. 03HumanNot a test of Glucagon aloneNon-randomized trialActivity measurement

    In insulinoma patients, maximal insulin responses to glucagon and glucose showed no significant correlation.

    In plain wordsIn insulinoma patients, maximum insulin responses to glucagon and glucose did not significantly correlate.

    Peptide
    Glucagon
    Outcome
    No significant changeMaximum insulin correlation with glucose test
    Study

    n = 11

    Comparator
    Glucose test
    Outcome group
    Glycemic control · Endocrine and hormones

    Source sentences

    Summary
    There was no significant correlations between the maximal levels of plasma insulin in the glucagon test and the glucose test, the tolbutamide test or the arginine test.
    1 context sentence
    Summary · context
    The intravenous glucagon test was performed in 11 patients with insulinoma and the diagnostic significance of the test was studied in comparison with the glucose test, the tolbutamide test and the arginine test.

    In this study, Glucagon was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Glucagon.

  4. 04HumanNot a test of Glucagon aloneNon-randomized trialActivity measurement

    In insulinoma patients, maximal insulin responses to glucagon and tolbutamide showed no significant correlation.

    In plain wordsIn insulinoma patients, maximum insulin responses to glucagon and tolbutamide did not significantly correlate.

    Peptide
    Glucagon
    Outcome
    No significant changeMaximum insulin correlation with tolbutamide test
    Study

    n = 11

    Comparator
    Tolbutamide test
    Outcome group
    Glycemic control · Endocrine and hormones

    Source sentences

    Summary
    There was no significant correlations between the maximal levels of plasma insulin in the glucagon test and the glucose test, the tolbutamide test or the arginine test.
    1 context sentence
    Summary · context
    The intravenous glucagon test was performed in 11 patients with insulinoma and the diagnostic significance of the test was studied in comparison with the glucose test, the tolbutamide test and the arginine test.

    In this study, Glucagon was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Glucagon.

  5. 05HumanNot a test of Glucagon aloneNon-randomized trialActivity measurement

    In insulinoma patients, maximal insulin responses to glucagon and arginine showed no significant correlation.

    In plain wordsIn insulinoma patients, maximum insulin responses to glucagon and arginine did not significantly correlate.

    Peptide
    Glucagon
    Outcome
    No significant changeMaximum insulin correlation with arginine test
    Study

    n = 11

    Comparator
    Arginine test
    Outcome group
    Glycemic control · Endocrine and hormones

    Source sentences

    Summary
    There was no significant correlations between the maximal levels of plasma insulin in the glucagon test and the glucose test, the tolbutamide test or the arginine test.
    1 context sentence
    Summary · context
    The intravenous glucagon test was performed in 11 patients with insulinoma and the diagnostic significance of the test was studied in comparison with the glucose test, the tolbutamide test and the arginine test.

    In this study, Glucagon was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Glucagon.

  6. 06HumanNot a test of Glucagon aloneNon-randomized trialActivity measurement

    In patients with insulinoma, plasma insulin curves after glucagon differed markedly from those in normal controls.

    In plain wordsAfter glucagon, patients with insulinoma had markedly different insulin response curves compared with normal controls.

    Peptide
    Glucagon
    Outcome
    Direction not reportedPlasma insulin response curves
    Study

    n: not reported in source

    Comparator
    Normal controls
    Outcome group
    Glycemic control · Endocrine and hormones

    Source sentences

    Summary
    The curves of plasma insulin following the intravenous administration of glucagon were markedly different and strange in those patients with insulinoma compared with the normal controls.
    1 context sentence
    Summary · context
    The intravenous glucagon test was performed in 11 patients with insulinoma and the diagnostic significance of the test was studied in comparison with the glucose test, the tolbutamide test and the arginine test.

    In this study, Glucagon was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Glucagon.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.